FATE THERAPEUTICS INC - Common Stock, $0.001 par value per share (FATE)

Historical Holders from Q1 2014 to Q1 2025

Symbol
FATE on Nasdaq
CUSIP
31189P102
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
120M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
101M
Holdings value
$166M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
154
Number of buys
68
Number of sells
-88
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FATE THERAPEUTICS INC - Common Stock, $0.001 par value per share (FATE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 14.9% $14.1M 17.8M Redmile Group, LLC Dec 20, 2024

Institutional Holders of FATE THERAPEUTICS INC - Common Stock, $0.001 par value per share (FATE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 685K $541K -$110K $0.79 9
2024 Q4 101M $166M -$49.3M $1.65 154
2024 Q3 115M $401M -$26.3M $3.50 157
2024 Q2 122M $401M -$37.6M $3.28 175
2024 Q1 123M $903M +$212M $7.34 161
2023 Q4 95.3M $356M -$10.2M $3.74 150
2023 Q3 95.7M $203M -$40.8M $2.12 162
2023 Q2 109M $518M -$20.8M $4.76 180
2023 Q1 113M $641M -$47.8M $5.70 174
2022 Q4 104M $1.05B -$66M $10.09 217
2022 Q3 107M $2.4B -$56.5M $22.41 218
2022 Q2 109M $2.68B +$194M $24.78 207
2022 Q1 101M $3.91B +$153M $38.77 230
2021 Q4 96.1M $5.62B +$808K $58.51 235
2021 Q3 95.7M $5.67B +$43.2M $59.27 255
2021 Q2 93.8M $8.14B +$47.1M $86.79 265
2021 Q1 93.7M $7.73B +$547M $82.45 253
2020 Q4 82.5M $7.5B -$82.7M $90.93 240
2020 Q3 87.5M $3.5B +$83.7M $39.97 205
2020 Q2 85.7M $2.94B +$358M $34.31 197
2020 Q1 75.6M $1.68B +$78.8M $22.21 153
2019 Q4 72.2M $1.41B -$7.63M $19.57 144
2019 Q3 72.1M $1.12B +$168M $15.53 144
2019 Q2 62.2M $1.26B +$61.7M $20.30 132
2019 Q1 59.5M $1.05B +$39.2M $17.57 119
2018 Q4 57.3M $736M +$35.3M $12.83 120
2018 Q3 54.8M $891M +$191M $16.29 113
2018 Q2 43M $488M +$35.4M $11.34 101
2018 Q1 39.4M $385M +$46.9M $9.76 87
2017 Q4 35.3M $214M +$65.3M $6.11 77
2017 Q3 25.4M $101M -$4.41M $3.96 69
2017 Q2 26.6M $86.2M +$4.82M $3.24 56
2017 Q1 25M $114M +$8.81M $4.55 50
2016 Q4 23.1M $57.9M +$8.8M $2.51 33
2016 Q3 19.5M $60.8M +$17.1M $3.12 36
2016 Q2 14.1M $23.9M -$3.1M $1.70 37
2016 Q1 15.8M $28.4M -$9.46M $1.80 42
2015 Q4 18.6M $62.7M -$726K $3.37 51
2015 Q3 18.3M $97.8M +$1.77M $5.33 41
2015 Q2 18M $116M +$47.8M $6.47 36
2015 Q1 10.6M $51.9M +$1.63M $4.89 25
2014 Q4 10.3M $51.7M -$3.44K $5.02 23
2014 Q3 10.3M $52.6M +$2.08M $5.10 22
2014 Q2 9.85M $62.4M +$1.72M $6.31 21
2014 Q1 9.56M $92.8M +$30.7M $9.74 21